Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

The NHS at 70: celebrations, renewed reforms and difficult choices

Health service remains popular with public, but faces daunting need for radical change

- PMLiVE

Trial data suggest Abivax’ drug may clear latent HIV

The drug reduced HIV DNA in cells over 28 days

Can new data aggregators shift the balance of power away from pharma?

Making data a core competence

- PMLiVE

Healthcare Comms news

Porterhouse unveils new website, Executive Insight opens new London base, plus Lucid's 'Thirsty Thursday'

- PMLiVE

Pegasus’ suicide prevention campaign wins at Communiqué

Small Talk Saves Lives scoops awards in Excellence in Media Relations and Excellence in Public Health Communications.

- PMLiVE

CGRP migraine drugs need prior approval for use, recommends ICER

Suggests clinicians should confirm that patients have tried other therapies prior to using CGRP inhibitors

- PMLiVE

Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

A round-up from pharma, biotech and healthcare

Trending: using social media to understand your pharma market

Blue Latitude Health Senior Associate Consultant Jiayi Chen explains how you can use social media to get under the skin of customers and your competition.

Blue Latitude Health

- PMLiVE

Anavex sets up trial of ‘triple-action’ Alzheimer’s drug

US biotech's novel drug is latest to join war on Alzheimer's

Trump attempts The Art of the Deal with pharma

Yet incendiary language, bullying and threats rarely lead to a deal

SWITCHED ONcology

We bring together the experts. The patients. The scientists. The technologists. The creatives. We unite powerful insights to make science mean something real. We are stronger together. We are Switched...

Havas Lynx

- PMLiVE

Alcon spin-off prompts Novartis downgrade by Moody’s

Selling off Alcon concentrates business in riskier areas

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links